13D Filing: OrbiMed Advisors and Roka Bioscience Inc. (ROKA)

Page 7 of 11

Page 7 of 11 – SEC Filing

In addition, Advisors and GP III, pursuant to their authority under the limited partnership agreements of OPI III and/or Associates III, prior to the date of this filing, caused OPI III and Associates III, as applicable, to enter into the agreements referred to in Item 6 below.
(c)
Seller
Date of Transaction
Transaction
Number of Shares
Price Per Share*
OPI III
October 3, 2017
Sold
199,718
$0.68
Associates III
October 3, 2017
Sold
1,899
$0.68
___________________________
* The Price Per Share reported above is a weighted average price.  The Shares were sold in multiple transactions at prices ranging from:  $0.66 to $0.71 (October 3, 2017).  Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares purchased at each separate price within the ranges set forth above.
Except as disclosed above and in Amendment No. 4, Amendment No. 5 and Amendment No. 6, the Reporting Persons have not effected any transactions in the Shares during the past sixty (60) days.
(d)           Not applicable.
(e)           Not applicable.
Item 6. Contracts, Arrangements, Understandings or Relationship with Respect to Securities of the Issuer
In addition to the relationships between the Reporting Persons described in Items 2, 3 and 5, GP III is the sole general partner of OPI III, pursuant to the terms of the limited partnership agreement of OPI III.  Advisors is the sole managing member of GP III, pursuant to the terms of the limited liability company agreement of GP III.  Advisors is also the sole general partner of Associates III, pursuant to the terms of the limited partnership agreement of Associates III.  Pursuant to these agreements and relationships, Advisors and GP III have shared discretionary investment management authority with respect to the assets of OPI III.  Such authority includes the power of GP III to vote and otherwise dispose of securities purchased by OPI III.  Advisors also has discretionary investment management authority with respect to the assets of Associates III and, as a result, has the power to direct the vote and disposition of the securities of the Issuer held by Associates III.  Isaly, pursuant to his authority as the managing member of, and owner of a controlling interest in, Advisors, also has shared discretionary power to direct the vote and the disposition of the securities of the Issuer held by OPI III and Associates III.  The number of outstanding Shares held of record by OPI III is zero, and the number of Warrants held of record by OPI III is 566,037. The number of outstanding Shares held of record by Associates III is zero and the number of Warrants held of record by Associates III is 5,391. Advisors and Isaly may be considered to hold indirectly 571,428 Warrants, and GP III may be considered to hold indirectly 566,037 Warrants.
Item 7. Materials to Be Filed as Exhibits
Exhibit
Description
1.
Joint Filing Agreement among OrbiMed Advisors LLC, OrbiMed Capital GP III LLC and Samuel D. Isaly.

Follow Roka Bioscience Inc. (NASDAQ:ROKA)

Page 7 of 11